The Proteomic Landscape of Triple-Negative Breast Cancer

Robert T. Lawrence, Elizabeth M. Perez, Daniel Hernández, Chris P. Miller, Kelsey M. Haas, Hanna Y. Irie, Su In Lee, Anthony C. Blau, Judit Villén

Research output: Contribution to journalArticlepeer-review

156 Scopus citations


Triple-negative breast cancer is a heterogeneous disease characterized by poor clinical outcomes and a shortage of targeted treatment options. To discover molecular features of triple-negative breast cancer, we performed quantitative proteomics analysis of twenty human-derived breast cell lines and four primary breast tumors to a depth of more than 12,000 distinct proteins. We used this data to identify breast cancer subtypes at the protein level and demonstrate the precise quantification of biomarkers, signaling proteins, and biological pathways by mass spectrometry. We integrated proteomics data with exome sequence resources to identify genomic aberrations that affect protein expression. We performed a high-throughput drug screen to identify protein markers of drug sensitivity and understand the mechanisms of drug resistance. The genome and proteome provide complementary information that, when combined, yield a powerful engine for therapeutic discovery. This resource is available to the cancer research community to catalyze further analysis and investigation.

Original languageEnglish
Pages (from-to)630-644
Number of pages15
JournalCell Reports
Issue number4
StatePublished - 28 Apr 2015


Dive into the research topics of 'The Proteomic Landscape of Triple-Negative Breast Cancer'. Together they form a unique fingerprint.

Cite this